The high expression of GPC1 on the surface of PDAC cells, its involvement in tumor progression and its role in the immunosuppressive tumor microenvironment prompted the development of a novel anti-GPC1 IgM mAb (AT101) for the treatment of PDAC patients. This evidence concerns the gene CD40LG and neoplasm.